Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $210.47, giving the company a market capitalization of 506.89B. It carries a P/E multiple of 20.20 and pays a dividend yield of 2.5%.
On 2025-12-18, Johnson & Johnson(JNJ) stock moved within a range of $208.46 to $211.59. With shares now at $210.47, the stock is trading +1.0% above its intraday low and -0.5% below the session's peak.
Trading volume for Johnson & Johnson(JNJ) stock has reached 8.46M, versus its average volume of 8.65M.
The stock's 52-week range extends from a low of $140.68 to a high of $215.19.
The stock's 52-week range extends from a low of $140.68 to a high of $215.19.
JNJ News
Johnson & Johnson “announced that the FDA approved RYBREVANT FASPRO, amivantamab and hyaluronidase-lpuj, the first and only subcutaneously administered therapy...
RBC Capital raised the firm’s price target on Johnson & Johnson to $240 from $230 and keeps an Outperform rating on the shares as part of a broader research not...
Johnson & Johnson (JNJ) just secured FDA approval for Akeega, a targeted combo therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer, a nich...
Analyst ratings
56%
of 27 ratingsMore JNJ News
The U.S. Food and Drug Administration on Monday awarded a national priority voucher to Johnson & Johnson’s (NYSE:JNJ) Tecvayli (teclistamab) in combination with...
The U.S. stock markets ended the week mostly lower, with the tech-heavy Nasdaq Composite and the S&P 500 slipping by 1.49% and 0.28%, respectively, due to a sha...
If you are wondering whether Johnson & Johnson is still a buy after its big run, you are not alone. This article is going to focus squarely on what the current...
Johnson & Johnson announced the U.S. Food and Drug Administration, FDA, approved the supplemental New Drug Application, sNDA, for AKEEGA plus prednisone for the...
(RTTNews) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application (sNDA) for AKEEGA—a...
Key Points A notable bank and a major investment management firm bought more shares of Johnson & Johnson. The healthcare giant has performed well this year de...
Johnson & Johnson has recently reported Phase 3 data showing that TECVAYLI plus DARZALEX FASPRO cut the risk of disease progression or death versus standard reg...